AntriaBio

Corcept Therapeutics

Radius Health

Crinetics Pharmaceuticals

Spruce Biosciences

MannKind Corporation

2 PubMed publications found for AntriaBio

Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes.

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).

SW convergence: 50/100 (Neutral), 0 bullish / 1 bearish signals

<article class="bts-verified-summary" data-ticker="ANTE">
<p>AntriaBio (ANTE) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>ANTE has 1 Form 4 insider filing recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22ANTE%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR

AntriaBio (ANTE) — BioTechSigns Verified Summary

AntriaBio (ANTE) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

ANTE has 1 Form 4 insider filing recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22ANTE%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11